Khalid Qaderdan

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

Marieke E. Gimbel, Khalid Qaderdan, Laura M. Willemsen et al. · The Lancet · 2020 · 342 citations · Full text

Thrombosis, Popular Age, Cardiovascular Disease +9

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Thomas O. Bergmeijer, Paul W.A. Janssen, Jurjan C. Schipper et al. · American Heart Journal · 2014 · 81 citations

Thrombosis, Percutaneous Coronary Intervention, Antiplatelet Therapy +12

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study

Khalid Qaderdan, Maycel Ishak, Antonius A.C.M. Heestermans et al. · American Heart Journal · 2015 · 48 citations

Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI—the POPular Risk Score study

Paul W.A. Janssen, Thomas O. Bergmeijer, Gert-Jan A. Vos et al. · European Journal of Clinical Pharmacology · 2019 · 23 citations

Non-pharmacological Intervention, P2y12 Inhibitor Treatment, Clinical Epidemiology +6

Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials

Khalid Qaderdan, G.A. Vos, Thomas McAndrew et al. · American Heart Journal · 2017 · 16 citations

Percutaneous Coronary Intervention, Thrombosis, Cardiovascular Disease +11